Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Liabilities and Shareholders Equity (2022 - 2025)

Stoke Therapeutics (STOK) has 4 years of Liabilities and Shareholders Equity data on record, last reported at $360.3 million in Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity rose 22.82% year-over-year to $360.3 million; the TTM value through Sep 2025 reached $1.4 billion, up 37.56%, while the annual FY2024 figure was $271.6 million, 18.92% up from the prior year.
  • Liabilities and Shareholders Equity reached $360.3 million in Q3 2025 per STOK's latest filing, down from $384.5 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $406.9 million in Q1 2025 and bottomed at $205.2 million in Q1 2024.
  • Average Liabilities and Shareholders Equity over 4 years is $292.5 million, with a median of $281.8 million recorded in 2023.
  • Peak YoY movement for Liabilities and Shareholders Equity: decreased 27.19% in 2024, then skyrocketed 98.31% in 2025.
  • A 4-year view of Liabilities and Shareholders Equity shows it stood at $256.1 million in 2022, then decreased by 10.83% to $228.3 million in 2023, then rose by 18.92% to $271.6 million in 2024, then skyrocketed by 32.67% to $360.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $360.3 million in Q3 2025, $384.5 million in Q2 2025, and $406.9 million in Q1 2025.